Anticoagulation Medicine in Surgical Repair for Total Anomalous Pulmonary Venous Connection

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Total anomalous pulmonary venous connection (TAPVC) is a complex congenital heart disease, requiring surgical repair. Pulmonary venous obstruction (PVO) is the major complication, with limited effective reinterventions and poor outcomes. This trial aims at investigating that postoperative anticoagulant management reduce the incidence of PVO.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangdong Provincial People's Hospital
• Treatments: Anticoagulants; Aspirin; Calcium heparin; Heparin; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• 1. Infants and neonates who are diagnosed with TAPVC

• 2. Infants and neonates who undergo initial surgical repair for TAPVC

Exclusion Criteria:

• 1. Concommitant diagnosis including functional single ventricular, double outlet right ventricle, tricuspid atresia, pulmonary atresia or transposition of the great arteries.

• 2. Older than 1-year-old.